- Home
- BAC vs ABBV Comparison
BAC vs ABBV Comparison
Compare BAC & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BAC | ABBV |
|---|---|---|
| Founded | 1784 | 2012 |
| Country | United States | United States |
| Employees | 213000 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 364.1B | 358.5B |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | BAC | ABBV |
|---|---|---|
| Price | $51.73 | $216.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 18 |
| Target Price | $60.34 | ★ $253.71 |
| AVG Volume (30 Days) | ★ 29.1M | 4.7M |
| Earning Date | 04-15-2026 | 04-29-2026 |
| Dividend Yield | 2.12% | ★ 3.39% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | ★ $61,160,000,000.00 |
| Revenue This Year | $13.11 | $11.87 |
| Revenue Next Year | $5.80 | $8.12 |
| P/E Ratio | ★ $14.01 | $552.10 |
| Revenue Growth | N/A | ★ 8.57 |
| 52 Week Low | $43.30 | $181.75 |
| 52 Week High | $57.55 | $244.81 |
Technical Indicators
Market Signals| Indicator | BAC | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 52.28 | 62.00 |
| Support Level | $51.35 | $209.88 |
| Resistance Level | $52.86 | $234.00 |
| Average True Range (ATR) | 1.05 | 4.72 |
| MACD | -0.05 | 1.45 |
| Stochastic Oscillator | 49.49 | 84.19 |
Price Performance
Historical ComparisonAbout BAC Bank of America Corporation
Bank of America is a formidable financial titan with a $3.5 trillion balance sheet and a cornerstone of the American economy, holding the second-largest deposit market share in the United States. While the firm has maintained its stronghold among middle-market and retail clientele domestically, Bank of America has continued to hold its own on the global stage, as evidenced by its fourth-largest global trading operation and an investment banking division that regularly finishes in the top four in global league tables. The firm is organized across four segments: consumer banking, global wealth and investment management, global banking, and global markets.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.